Rumi Therapeutics Announces Licensing Agreement With Enthorin Therapeutics to Advance RTX-7340, an IND-Ready PDE2 Inhibitor, for Fragile X Syndrome
November 11, 2026
NEW YORK--(BUSINESS WIRE)--Rumi Therapeutics, a drug-development company...
Read More